Venous thromboembolism (VTE) is highly prevalent in people undergoing treatment for cancer.

Serious consequences for cancer patients include the need for hospitalization, long-term anticoagulation, and death. Recent large clinical trials have addressed thromboprophylaxis in the outpatient setting with potential benefit of reducing morbidity and mortality. However, these studies also show considerable variation in underlying risk. This webinar will review the burden of VTE in cancer patients and discuss the importance of VTE risk assessment for guiding outpatient prevention practices.